Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

The new vials – priced at $399 and $549, respectively, for a month's supply – are a lower-cost alternative to the current injector pen formulation of Zepbound and are easier to produce.

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...

Chief executive Chris Viehbacher said on Biogen's results call that a plan to extend the use of the subcutaneous injector into the induction phase of treatment could be a "game changer." ...

This hormone slows the rate of how the stomach is emptied and regulates blood sugar. Amycretin also works slightly differently than Eli Lilly’s Zepbound and Viking Therapeutics’ experimental VK-2735, ...

Of those, over 215,000 had been prescribed a glucagon-like peptide-1 (GLP-1) agonist receptor — the class of drugs that includes Ozempic, Wegovy, Mounjaro, Zepbound, and others — and 1.7 ...

One reason is pressure from American drugmaker Eli Lilly, which makes competing products Zepbound and Mounjaro (alternatives to Wegovy and Ozempic, respectively). Novo’s stock fell slightly in ...